Emerging Therapeutic Biomarkers in Endometrial Cancer

Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/acquired drug resistance and unexpected side effects on normal tissues. New studies that aim to target both genetic and epigenetic alterations (noncoding microRNA) underlying malignant properties of tumor cells and to specifically attack tumor cells using cell surface markers overexpressed in tumor tissue are emerging. More importantly, strategies that disrupt the cancer stem cell/epithelial-mesenchymal transition-dependent signals and reactivate antitumor immune responses would bring new hope for complete elimination of all cell compartments in endometrial cancer. We briefly review the current status of molecular therapies tested in clinical trials and mainly discuss the potential therapeutic candidates that are possibly used to develop more effective and specific therapies against endometrial cancer progression and metastasis.

[1]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[2]  H. Sasano,et al.  Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. , 1995, Human pathology.

[3]  G. Riggins,et al.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.

[4]  Soma Das,et al.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma , 2001, International journal of cancer.

[5]  J. Herman,et al.  Abnormalities of the APC/beta-catenin pathway in endometrial cancer. , 2002, Oncogene.

[6]  J. Herman,et al.  Abnormalities of the APC/β-catenin pathway in endometrial cancer , 2002, Oncogene.

[7]  K. Miyazaki,et al.  Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. , 2002, Human pathology.

[8]  C. Holland,et al.  Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer , 2003, British Journal of Cancer.

[9]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[10]  G. Soma,et al.  Multiple roles of cyclooxygenase-2 in endometrial cancer. , 2005, Anticancer research.

[11]  G. Fleming,et al.  Rare uterine cancers. , 2005, The Lancet. Oncology.

[12]  G. Dontu,et al.  Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. , 2006, Cancer research.

[13]  M. Mimeault,et al.  Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells , 2006, International journal of cancer.

[14]  W. Hall,et al.  Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy , 2007, Journal of Neuro-Oncology.

[15]  Z. Weng,et al.  Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue , 2006, International Journal of Gynecologic Cancer.

[16]  W. Hall,et al.  Expression of MHC I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy , 2006, Journal of Neuro-Oncology.

[17]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[18]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[19]  H. Kashima,et al.  Overexpression of Hedgehog Signaling Molecules and Its Involvement in the Proliferation of Endometrial Carcinoma Cells , 2007, Clinical Cancer Research.

[20]  A. Berchuck,et al.  Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. , 2007, Gynecologic oncology.

[21]  M. Davy,et al.  Serous carcinoma of the uterus—determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation , 2007, International Journal of Gynecologic Cancer.

[22]  Brian Keith,et al.  Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.

[23]  M. Hollingsworth,et al.  Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins , 2007, Journal of cellular biochemistry.

[24]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[25]  G. Tortora,et al.  Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. , 2007, Differentiation; research in biological diversity.

[26]  Phuong Dinh,et al.  Review: side effects of approved molecular targeted therapies in solid cancers. , 2007, The oncologist.

[27]  M. Marizzoni,et al.  Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma , 2007, Cancer.

[28]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[29]  A. Mariani,et al.  Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. , 2008, Gynecologic oncology.

[30]  F. Bozzo,et al.  Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. , 2008, Carcinogenesis.

[31]  P. Carter,et al.  CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers , 2008, British Journal of Cancer.

[32]  M. K. Siu,et al.  Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis , 2008, International journal of cancer.

[33]  X. Guan,et al.  CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.

[34]  N. Chatterjee,et al.  PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. , 2008, Cancer research.

[35]  D. Coppola,et al.  Twist Is Transcriptionally Induced by Activation of STAT3 and Mediates STAT3 Oncogenic Function* , 2008, Journal of Biological Chemistry.

[36]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[37]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[38]  Multiple molecular mechanisms sustain hypoxia - dependent epithelial - mesenchymal transition and increased invasiveness in human cancer cells , 2008 .

[39]  D. Pouniotis,et al.  Immunomodulation in Endometrial Cancer , 2008, International Journal of Gynecologic Cancer.

[40]  S. Tavangar,et al.  Altered PTEN expression ; a diagnostic marker for differentiating normal , hyperplastic and neoplastic endometrium , 2009 .

[41]  Markus Munz,et al.  The emerging role of EpCAM in cancer and stem cell signaling. , 2009, Cancer research.

[42]  R. Cubas,et al.  Trop2: a possible therapeutic target for late stage epithelial carcinomas. , 2009, Biochimica et biophysica acta.

[43]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[44]  Yutaka Kawakami,et al.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. , 2009, Cancer cell.

[45]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[46]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[47]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[48]  A. Sood,et al.  EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer , 2009, Cancer.

[49]  A. Mariani,et al.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer , 2008, British Journal of Cancer.

[50]  Evelyn R. Hermes-DeSantis,et al.  Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[51]  S. Mok,et al.  Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women , 2009, International journal of cancer.

[52]  B. Rueda,et al.  Evidence for cancer stem cells in human endometrial carcinoma. , 2009, Cancer research.

[53]  C. Gondi,et al.  Concepts in in vivo siRNA delivery for cancer therapy , 2009, Journal of cellular physiology.

[54]  H. V. van Doorn,et al.  Progesterone Inhibition of Wnt/β-Catenin Signaling in Normal Endometrium and Endometrial Cancer , 2009, Clinical Cancer Research.

[55]  A. Sood,et al.  EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma , 2010, Clinical Cancer Research.

[56]  T. Yau,et al.  A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. , 2010, Cell stem cell.

[57]  J. Kolesar,et al.  Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[58]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[59]  P. Altevogt,et al.  Up‐regulation of L1CAM is linked to loss of hormone receptors and E‐cadherin in aggressive subtypes of endometrial carcinomas , 2010, The Journal of pathology.

[60]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[62]  G. Coukos,et al.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. , 2010, Gynecologic oncology.

[63]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[64]  S. Kyo,et al.  Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. , 2010, Human pathology.

[65]  F. Casagrande,et al.  Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201) , 2010, Molecular Cancer Therapeutics.

[66]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[67]  A. Ashworth,et al.  Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.

[68]  K. Hasegawa,et al.  Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers , 2011, Archives of Gynecology and Obstetrics.

[69]  P. Dong,et al.  MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1 , 2011, Molecular Cancer.

[70]  S. Mittal,et al.  Emerging strategies for EphA2 receptor targeting for cancer therapeutics , 2011, Expert opinion on therapeutic targets.

[71]  D. Sgroi,et al.  A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas , 2011, Clinical Cancer Research.

[72]  L. Zhai,et al.  Prognostic Value of E-Cadherin Expression and CDH1 Promoter Methylation in Patients With Endometrial Carcinoma , 2011, Cancer investigation.

[73]  Sean P. Palecek,et al.  Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors , 2012, BMC Cancer.

[74]  M. Montecino,et al.  Wnt/β-Catenin Signaling Enhances Cyclooxygenase-2 (COX2) Transcriptional Activity in Gastric Cancer Cells , 2011, PloS one.

[75]  Song Liu,et al.  Gene Expression Profiles in Stage I Uterine Serous Carcinoma in Comparison to Grade 3 and Grade 1 Stage I Endometrioid Adenocarcinoma , 2011, PloS one.

[76]  J. Weidhaas,et al.  Cancer microRNAs: from subtype profiling to predictors of response to therapy. , 2011, Trends in molecular medicine.

[77]  T. Taxt,et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[78]  A. Nickles Fader,et al.  Uterine Papillary Serous Carcinoma , 2011, Clinical obstetrics and gynecology.

[79]  J. Inazawa,et al.  miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. , 2011, Cancer research.

[80]  T. Rutherford,et al.  Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody , 2011, Cancer.

[81]  B. Weigelt,et al.  Molecular targets and targeted therapeutics in endometrial cancer , 2012, Current opinion in oncology.

[82]  I. Mackenzie,et al.  Cancer stem cells and EMT in carcinoma , 2012, Cancer and Metastasis Reviews.

[83]  F. Claret,et al.  Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer , 2012, Front. Oncol..

[84]  P. Altevogt,et al.  Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. , 2012, Cancer letters.

[85]  Kiyoko Kato.  Endometrial cancer stem cells: a new target for cancer therapy. , 2012, Anticancer research.

[86]  Jia Li,et al.  DNMT Inhibitors and HDAC Inhibitors Regulate E-Cadherin and Bcl-2 Expression in Endometrial Carcinoma in vitro and in vivo , 2012, Chemotherapy.

[87]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[88]  Peter Dirks,et al.  Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.

[89]  E. Oliva,et al.  Molecular Profile of Grade 3 Endometrioid Endometrial Carcinoma: Is it a Type I or Type II Endometrial Carcinoma? , 2012, The American journal of surgical pathology.

[90]  Jorge S Reis-Filho,et al.  Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.

[91]  R. Coleman,et al.  The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer , 2012, Clinical Cancer Research.

[92]  Li Ma,et al.  MicroRNA control of epithelial–mesenchymal transition and metastasis , 2012, Cancer and Metastasis Reviews.

[93]  A. Chatterjee,et al.  Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance , 2012, Cell cycle.

[94]  P. Altevogt,et al.  L1CAM , 2012, Cell adhesion & migration.

[95]  P. Pelicci,et al.  Regulation of self‐renewal in normal and cancer stem cells , 2012, The FEBS journal.

[96]  E. Sartori,et al.  Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma , 2012, BMC Clinical Pathology.

[97]  H. Xia,et al.  MicroRNAs involved in regulating epithelial–mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics , 2012, Cancer Gene Therapy.

[98]  R. Gilbertson,et al.  Cancer: Resolving the stem-cell debate , 2012, Nature.

[99]  M. Fortini,et al.  Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. , 2012, Seminars in cell & developmental biology.

[100]  V. Stearns,et al.  Epigenetics as a Therapeutic Target in Breast Cancer , 2012, Journal of Mammary Gland Biology and Neoplasia.

[101]  P. Dong,et al.  Prognostic significance of miR-194 in endometrial cancer , 2013, Biomarker Research.

[102]  H. Kashima,et al.  Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells , 2012, Histopathology.

[103]  R. Schneider-Stock,et al.  hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases , 2012, Clinical & Experimental Metastasis.

[104]  Kiyoko Kato.  Stem cells in human normal endometrium and endometrial cancer cells: Characterization of side population cells , 2012, The Kaohsiung journal of medical sciences.

[105]  O. Gires,et al.  EpCAM and its potential role in tumor-initiating cells , 2012, Cell adhesion & migration.

[106]  M. Bushell,et al.  microRNAs in cancer management. , 2012, The Lancet. Oncology.

[107]  R. Berkowitz,et al.  Dysregulation of microRNA‐204 mediates migration and invasion of endometrial cancer by regulating FOXC1 , 2012, International journal of cancer.

[108]  P. Dong,et al.  Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis , 2012, Oncogene.

[109]  M. Shyu,et al.  MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer. , 2013, Gynecologic oncology.

[110]  C. Pecqueur,et al.  Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells , 2013, International journal of cell biology.

[111]  K. Kalland,et al.  Lack of Estrogen Receptor-α Is Associated with Epithelial–Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma , 2013, Clinical Cancer Research.

[112]  Kiyoko Kato,et al.  The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. , 2013, Gynecologic oncology.

[113]  X. Matías-Guiu,et al.  Molecular pathology of endometrial carcinoma , 2013, Histopathology.

[114]  Junjie Xiao,et al.  MicroRNA Therapeutics. , 2015, Mini reviews in medicinal chemistry.